Question 1

Am I eligible to participate in this trial based on my family history and current health?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease clinical trial (NCT06996730). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease clinical trial (NCT06996730). Contact the study team or your healthcare provider for specific answers.

Question 3

How will the treatments be administered, and what will my visits look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease clinical trial (NCT06996730). Contact the study team or your healthcare provider for specific answers.

Question 4

What kind of monitoring will be done to assess my health during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease clinical trial (NCT06996730). Contact the study team or your healthcare provider for specific answers.

Question 5

How does this trial compare to other treatment options available for Alzheimer's?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease clinical trial (NCT06996730). Contact the study team or your healthcare provider for specific answers.

What this study is about